Comera Life Sciences Announces Issuance of U.S. Patent for Proprietary Excipients in SQore Platform


WOBURN, Mass.– Comera Life Sciences Holdings, Inc. (Nasdaq: CMRA), a life sciences company developing a new generation of bio-innovative biologic medicines to improve patient access, safety, and convenience, expanded its patent portfolio with the issuance of U.S. Patent No. 11,357,857 (the ‘857 patent), which provides Comera exclusive rights pertaining to certain excipients in its SQore™ platform as viscosity-lowering agents to significantly optimize filtration efficiency of protein solutions during the biologics manufacturing process. The ‘857 patent reflects a significant addition to Comera’s current intellectual property portfolio and expands the potential commercial applications of SQore, broadening patent protections beyond use in therapeutic antibody formulations to include manufacturing process enhancement.

“We believe that the ‘857 patent will more broadly protect SQore’s use in manufacturing process optimization and has the potential of expanding SQore’s commercial value in biologic manufacturing, as we work with our strategic partners to transform the delivery of biologics to benefit patient care,” said Jeff Hackman, Chief Executive Officer and Chairman of Comera. “We have been significantly investing in the scientific development of our SQore platform, and today’s patent issuance reflects our efforts to strengthen our intellectual property position for SQore.”

Filtration of protein solutions is a key component of the antibody manufacturing process and is utilized for sterilization, removal of impurities, and concentration of the active ingredient to allow for use as an injected medicine. The filtration steps can be time consuming, costly, and inefficient, and an increase in filtration rate could improve the economics of production. Comera believes that its SQore technology, by lowering viscosity of high concentration protein solutions, allows for high-throughput filtration and a significantly more efficient manufacturing process.

“The benefits of Comera’s viscosity-reducing SQore technology goes well-beyond enabling subcutaneous drug formulations,” said Alan Herman, Ph.D., a scientific advisor to Comera and former Chief Scientific Officer of Coherus Biosciences. “High viscosity encountered during the downstream processing phase of drug manufacturing can significantly reduce efficiency, so technologies like SQore that can lower viscosity offer the potential to greatly optimize production throughput of antibody formulations.”